MIRA Pharmaceuticals, Inc. MIRA shares soared to $1.87, an approximate 50.8% jump, during after-hours trading on Wednesday. What Happened: After the announcement of Mira-55, a synthetic analog of marijuana, providing pain relief comparable to morphine, the stock value of MIRA Pharmaceutical ...

Third-party analysis valued SKNY at $30.5 million and Mira at $30 million based on pipeline potential. SKNY to contribute $5 million in cash or assets to Mira at deal closing. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds ...

No adverse signs or brain lesions observed in any Ketamir-2-treated rats. MK-801 control group showed clear neurotoxicity, validating study design. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds profits in volatile markets.

Ketamir-2 reduced neuropathic pain in diabetic rats, with some returning to pre-diabetic sensitivity levels. In preclinical studies, Ketamir-2 outperformed pregabalin and gabapentin without dissociative side effects.

MIRA Pharmaceuticals to acquire SKNY Pharmaceuticals, integrating SKNY-1, a preclinical drug for weight loss and smoking cessation. The deal includes a $5 million capital infusion into MIRA, bolstering its financial position and expanding its pipeline. Feel unsure about the market's next move?